Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 Read more
Vertex Pharma bets on kidney disease treatment with $4.9 billion Alpine Immune deal By Reuters Read more